Mechanism of action

  • Gq protein-coupled receptor agonist → ↑ intracellular Ca²⁺ in myometrial cells → uterine contraction.
  • Stimulates myoepithelial cells in mammary tissue → milk ejection (“let-down” reflex).
  • Structural homology to Vasopressin (ADH) → cross-reacts w/ V2 receptors in renal collecting ducts at high doses.

Clinical indications

  • Postpartum Hemorrhage (PPH): 1st-line agent for prevention and treatment of uterine atony.
  • Labor Induction / Augmentation: Indicated for protracted or arrested labor due to inadequate uterine contractions.
  • Abortion Management: Adjunct for incomplete, inevitable, or missed abortion in 2nd trimester.

Adverse effects & toxicity

  • Hyponatremia / Water Intoxication: c
    • Mechanism: ADH-like V2 receptor agonist effect causing free water retention.
    • Clinical Picture: Severe hyponatremia, cerebral edema, seizures, encephalopathy, coma.
    • Trigger: High-dose, prolonged IV infusion combined w/ hypotonic IV fluids (e.g., D5W).
  • Uterine Tachysystole:
    • Definition: > 5 contractions in 10 minutes over a 30-minute window.
    • Complication: Uteroplacental insufficiency → fetal late decelerations, hypoxia, acidosis.
  • Hypotension:
    • Occurs w/ rapid IV push due to systemic vasodilation; must give via controlled IV infusion.
  • Uterine Rupture:
    • Increased risk in pts w/ prior C-section or myomectomy.

Management of oxytocin complications

  • Uterine Tachysystole + Abnormal Fetal Heart Rate:
    1. Discontinue Oxytocin infusion immediately.
    2. Maternal repositioning (left lateral), O2 administration, IVF bolus.
    3. If non-reassuring trace persists: Administer tocolytics (e.g., terbutaline).
  • Oxytocin-Induced Hyponatremia / Seizures:
    1. Discontinue Oxytocin infusion and fluid-restrict.
    2. Administer 3% hypertonic saline for active seizures or severe encephalopathy.